Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
$2.06
+1.0%
$71.92
$27.35
$73.10
$53.71M-1.2267,931 shs13,855 shs
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$5.03
+2.0%
$5.76
$1.38
$7.61
$82.10M1.253,172 shs26,281 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$3.26
+2.5%
$3.85
$1.80
$5.30
$36.24M0.4734,048 shs8,334 shs
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$13.56
-3.2%
$14.38
$3.80
$18.15
$402.36M2.08139,139 shs44,430 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
+0.98%-4.63%-6.36%+15.08%+0.49%
BrainsWay Ltd. stock logo
BWAY
BrainsWay
+1.93%-0.40%-7.37%-17.68%+224.52%
LENSAR, Inc. stock logo
LNSR
LENSAR
+2.52%+6.54%-6.05%-9.44%+25.38%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-3.21%-1.38%+4.07%-7.00%+205.41%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
0.7079 of 5 stars
3.53.00.00.00.00.00.0
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.6202 of 5 stars
3.35.00.00.02.50.80.6
LENSAR, Inc. stock logo
LNSR
LENSAR
2.24 of 5 stars
3.53.00.00.02.62.50.0
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.5306 of 5 stars
3.43.00.00.01.94.20.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
3.00
Buy$6.78228.88% Upside
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.67
Moderate Buy$7.0039.17% Upside
LENSAR, Inc. stock logo
LNSR
LENSAR
3.00
Buy$8.00145.40% Upside
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.86
Moderate Buy$15.6715.54% Upside

Current Analyst Ratings

Latest BEAT, NPCE, LNSR, and BWAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/25/2024
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$8.00
3/19/2024
LENSAR, Inc. stock logo
LNSR
LENSAR
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
3/14/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$16.00 ➝ $20.00
3/11/2024
BrainsWay Ltd. stock logo
BWAY
BrainsWay
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $13.00
3/6/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.00
2/22/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$9.00 ➝ $16.00
1/30/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
1/30/2024
NeuroPace, Inc. stock logo
NPCE
NeuroPace
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
N/AN/AN/AN/A$0.61 per shareN/A
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$31.78M2.63N/AN/A$2.50 per share2.01
LENSAR, Inc. stock logo
LNSR
LENSAR
$42.16M0.88N/AN/A$2.97 per share1.10
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$65.42M5.95N/AN/A$0.79 per share17.16

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
-$14.64M-$0.92N/AN/AN/A-106.91%-97.80%5/9/2024 (Estimated)
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$4.20M-$0.13N/A62.88N/A-13.20%-10.05%-6.88%5/15/2024 (Estimated)
LENSAR, Inc. stock logo
LNSR
LENSAR
-$14.38M-$1.79N/AN/A-34.11%-40.53%-21.83%5/20/2024 (Estimated)
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$32.96M-$1.28N/AN/AN/A-50.38%-153.76%-31.73%5/8/2024 (Confirmed)

Latest BEAT, NPCE, LNSR, and BWAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.32N/A+$0.32N/AN/AN/A  
3/20/2024Q4 2023
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
-$0.12-$0.13-$0.01-$0.13N/AN/A    
3/6/202412/31/2023
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$0.03-$0.01+$0.02N/A$8.40 million$9.03 million    
3/5/2024Q4 2023
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.33-$0.23+$0.10-$0.23$17.74 million$18.01 million    
3/4/202412/31/2023
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.22-$0.22N/A-$0.35N/A$12.11 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
N/AN/AN/AN/AN/A
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/AN/AN/AN/AN/A
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
N/A
14.09
14.09
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/A
5.68
5.30
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
3.99
2.64
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.76
5.71
5.02

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
7.77%
BrainsWay Ltd. stock logo
BWAY
BrainsWay
30.11%
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%

Insider Ownership

CompanyInsider Ownership
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
7.32%
BrainsWay Ltd. stock logo
BWAY
BrainsWay
19.00%
LENSAR, Inc. stock logo
LNSR
LENSAR
38.52%
NeuroPace, Inc. stock logo
NPCE
NeuroPace
27.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioTelemetry, Inc. stock logo
BEAT
BioTelemetry
1,70026.33 million24.40 millionNot Optionable
BrainsWay Ltd. stock logo
BWAY
BrainsWay
13416.64 million13.48 millionNot Optionable
LENSAR, Inc. stock logo
LNSR
LENSAR
13011.40 million7.01 millionOptionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17128.72 million19.06 millionOptionable

BEAT, NPCE, LNSR, and BWAY Headlines

SourceHeadline
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 24,609 SharesNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 24,609 Shares
americanbankingnews.com - April 24 at 4:56 AM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $345,756.45 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $345,756.45 in Stock
insidertrades.com - April 24 at 4:47 AM
Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 24,609 Shares of StockInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 24,609 Shares of Stock
marketbeat.com - April 23 at 9:13 PM
OrbiMed Advisors sells shares in NeuroPace worth over $238,000OrbiMed Advisors sells shares in NeuroPace worth over $238,000
investing.com - April 20 at 7:32 AM
Orbimed Advisors Llc Sells 2,623 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOrbimed Advisors Llc Sells 2,623 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock
americanbankingnews.com - April 20 at 6:14 AM
Orbimed Advisors Llc Sells 14,069 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOrbimed Advisors Llc Sells 14,069 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock
americanbankingnews.com - April 20 at 5:20 AM
Insider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of StockInsider Selling: NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells 2,623 Shares of Stock
insidertrades.com - April 19 at 6:53 AM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $36,879.38 in Stock
marketbeat.com - April 18 at 6:51 PM
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
globenewswire.com - April 17 at 4:05 PM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 SharesNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Orbimed Advisors Llc Sells 461,899 Shares
americanbankingnews.com - April 16 at 4:18 AM
NeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in StockNeuroPace, Inc. (NASDAQ:NPCE) Major Shareholder Sells $6,692,916.51 in Stock
insidertrades.com - April 16 at 4:17 AM
Orbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) StockOrbimed Advisors Llc Sells 461,899 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock
marketbeat.com - April 15 at 6:47 PM
Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)Head-To-Head Analysis: NeuroPace (NASDAQ:NPCE) and Akili (NASDAQ:AKLI)
americanbankingnews.com - April 15 at 2:00 AM
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from BrokeragesNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages
marketbeat.com - April 14 at 4:07 AM
Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%Short Interest in NeuroPace, Inc. (NASDAQ:NPCE) Grows By 178.0%
marketbeat.com - April 12 at 12:14 AM
NeuroPace (NASDAQ: NPCE)NeuroPace (NASDAQ: NPCE)
fool.com - April 10 at 3:47 PM
Kent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)Kent Lake Capital LLC Buys 96,529 Shares of NeuroPace, Inc. (NASDAQ:NPCE)
marketbeat.com - April 6 at 7:28 PM
Biggest mistake bond investors may make ahead of Fed rate cuts'Biggest mistake' bond investors may make ahead of Fed rate cuts
msn.com - April 4 at 7:38 PM
NeuroPace to Present at the Needham 23rd Annual Healthcare ConferenceNeuroPace to Present at the Needham 23rd Annual Healthcare Conference
globenewswire.com - March 27 at 4:05 PM
The Latest Analyst Ratings For NeuroPaceThe Latest Analyst Ratings For NeuroPace
markets.businessinsider.com - March 13 at 5:40 AM
NeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth DriversNeuroPace Secures Buy Rating from Analyst Mike Kratky Amid Positive Revenue Guidance and Growth Drivers
markets.businessinsider.com - March 7 at 1:04 PM
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call TranscriptNeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 1:04 PM
NeuroPace Full Year 2023 Earnings: EPS Beats ExpectationsNeuroPace Full Year 2023 Earnings: EPS Beats Expectations
finance.yahoo.com - March 7 at 8:04 AM
NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call TranscriptNeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript
seekingalpha.com - March 7 at 3:02 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

BioTelemetry logo

BioTelemetry

NASDAQ:BEAT
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
BrainsWay logo

BrainsWay

NASDAQ:BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
LENSAR logo

LENSAR

NASDAQ:LNSR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
NeuroPace logo

NeuroPace

NASDAQ:NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.